Published in Cancer Res on December 06, 2010
Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci U S A (2011) 1.76
Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A (2015) 1.51
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A (2012) 1.32
miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT. Oncogene (2013) 1.24
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res (2012) 1.21
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A (2013) 1.12
Does the microenvironment influence the cell types of origin for prostate cancer? Genes Dev (2013) 0.97
Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab (2011) 0.96
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy. Cancer Lett (2012) 0.93
Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol Cell Biol (2014) 0.92
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs (2013) 0.89
Collaboration of Kras and androgen receptor signaling stimulates EZH2 expression and tumor-propagating cells in prostate cancer. Cancer Res (2012) 0.88
Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases. Int J Biol Sci (2014) 0.87
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PLoS One (2011) 0.87
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl (2014) 0.86
Src signaling pathways in prostate cancer. Cancer Metastasis Rev (2014) 0.86
Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer. Clin Med Insights Urol (2013) 0.85
SRC: marker or actor in prostate cancer aggressiveness. Front Oncol (2014) 0.83
Role of signaling transduction pathways in development of castration-resistant prostate cancer. Prostate Cancer (2011) 0.83
Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. Oncotarget (2015) 0.82
Androgen-sensitive microsomal signaling networks coupled to the proliferation and differentiation of human prostate cancer cells. Genes Cancer (2011) 0.82
miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src. Cancer Res (2015) 0.82
Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase. Oncotarget (2015) 0.81
Lung cancer and lung injury: the dual role of ceramide. Handb Exp Pharmacol (2013) 0.81
CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines. Cancer Res (2014) 0.80
Differential requirement for Src family tyrosine kinases in the initiation, progression, and metastasis of prostate cancer. Mol Cancer Res (2014) 0.80
A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. Invest New Drugs (2014) 0.80
PI-3 kinase p110β: a therapeutic target in advanced prostate cancers. Am J Clin Exp Urol (2014) 0.80
Novel roles of Src in cancer cell epithelial-to-mesenchymal transition, vascular permeability, microinvasion and metastasis. Life Sci (2016) 0.78
ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents. Oncotarget (2015) 0.78
Src controls castration recurrence of CWR22 prostate cancer xenografts. Cancer Med (2013) 0.78
c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC. Oncotarget (2016) 0.77
Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass. Oncotarget (2015) 0.76
ING3 promotes prostate cancer growth by activating the androgen receptor. BMC Med (2017) 0.75
Gli Transcription Factors Mediate the Oncogenic Transformation of Prostate Basal Cells Induced by a Kras-Androgen Receptor Axis. J Biol Chem (2016) 0.75
v-Src Oncogene Induces Trop2 Proteolytic Activation via Cyclin D1. Cancer Res (2016) 0.75
Androgen receptor regulates SRC expression through microRNA-203. Oncotarget (2016) 0.75
Characterization of an Engineered Src Kinase to Study Src Signaling and Biology. Methods Mol Biol (2016) 0.75
Pim1 kinase regulates c-Kit gene translation. Exp Hematol Oncol (2016) 0.75
The prohibitin-repressive interaction with E2F1 is rapidly inhibited by androgen signalling in prostate cancer cells. Oncogenesis (2017) 0.75
Cancer statistics, 2007. CA Cancer J Clin (2007) 53.49
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol (2006) 23.04
Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell (2005) 9.84
Biomarkers for epithelial-mesenchymal transitions. J Clin Invest (2009) 8.76
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
A renaissance for SRC. Nat Rev Cancer (2004) 6.27
Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res (2006) 5.90
Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A (2006) 4.54
Identification of a tumour suppressor network opposing nuclear Akt function. Nature (2006) 3.68
The hunting of the Src. Nat Rev Mol Cell Biol (2001) 3.64
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
The interplay between Src family kinases and receptor tyrosine kinases. Oncogene (2004) 3.36
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci U S A (2003) 3.19
Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 3.16
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A (2009) 2.93
Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet (1999) 2.84
Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res (2008) 2.59
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 2.14
Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev (1997) 2.08
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A (2006) 1.93
Src and FAK signalling controls adhesion fate and the epithelial-to-mesenchymal transition. Curr Opin Cell Biol (2005) 1.85
Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol (2009) 1.75
Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol (2008) 1.69
Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res (2009) 1.63
Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res (2006) 1.62
SRC catalytic but not scaffolding function is needed for integrin-regulated tyrosine phosphorylation, cell migration, and cell spreading. Mol Cell Biol (2002) 1.61
Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res (2006) 1.56
The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell (2002) 1.56
Molecular markers of prostate cancer outcome. Eur J Cancer (2005) 1.52
SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin Cancer Res (2009) 1.47
Cell-specific regulation of androgen receptor phosphorylation in vivo. J Biol Chem (2005) 1.38
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene (2008) 1.33
Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol (2010) 1.27
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer. Cancer Treat Rev (2009) 1.22
Src as a therapeutic target in men with prostate cancer and bone metastases. BJU Int (2008) 1.11
The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. Cancer Res (2005) 1.08
No evidence of correlation between mutation at codon 531 of src and the risk of colon cancer in Chinese. Cancer Lett (2000) 0.97
Lack of activating c-SRC mutations at codon 531 in rectal cancer. Cancer Genet Cytogenet (2000) 0.95
Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer. Expert Opin Investig Drugs (2010) 0.94
Genomic approaches to outcome prediction in prostate cancer. Cancer (2009) 0.89
Transactivator and structurally optimized inducible lentiviral vectors. Mol Ther (2004) 0.88
Identification of a cell of origin for human prostate cancer. Science (2010) 6.33
Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci U S A (2006) 4.54
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci U S A (2005) 4.12
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell (2010) 3.41
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A (2008) 3.26
In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci U S A (2003) 3.19
The BCR-ABL story: bench to bedside and back. Annu Rev Immunol (2004) 3.00
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A (2009) 2.93
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol (2012) 2.89
Multistep synthesis of a radiolabeled imaging probe using integrated microfluidics. Science (2005) 2.83
Highly efficient capture of circulating tumor cells by using nanostructured silicon substrates with integrated chaotic micromixers. Angew Chem Int Ed Engl (2011) 2.79
Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov (2011) 2.77
The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell (2012) 2.69
Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A (2010) 2.69
Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells (2007) 2.50
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice. Hepatology (2014) 2.45
DNA-encoded antibody libraries: a unified platform for multiplexed cell sorting and detection of genes and proteins. J Am Chem Soc (2007) 2.42
NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell (2006) 2.29
Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog. Nat Med (2008) 2.24
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 2.14
PC3 is a cell line characteristic of prostatic small cell carcinoma. Prostate (2011) 2.13
Clinical application of a 3D ultrasound-guided prostate biopsy system. Urol Oncol (2011) 2.03
Isolation, cultivation and characterization of adult murine prostate stem cells. Nat Protoc (2010) 1.96
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci U S A (2006) 1.93
Selective regulation of lymphopoiesis and leukemogenesis by individual zinc fingers of Ikaros. Nat Immunol (2013) 1.88
mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab (2013) 1.86
Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol (2006) 1.80
Aging and cancer resistance in lymphoid progenitors are linked processes conferred by p16Ink4a and Arf. Genes Dev (2008) 1.79
Human prostate sphere-forming cells represent a subset of basal epithelial cells capable of glandular regeneration in vivo. Prostate (2010) 1.78
An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov (2011) 1.77
Differential transformation capacity of Src family kinases during the initiation of prostate cancer. Proc Natl Acad Sci U S A (2011) 1.76
Stem cells in prostate cancer initiation and progression. J Clin Invest (2007) 1.76
Migration to apoptotic "find-me" signals is mediated via the phagocyte receptor G2A. J Biol Chem (2007) 1.75
Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer (2013) 1.73
Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One (2010) 1.69
Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy. Cancer Discov (2013) 1.68
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J Urol (2013) 1.64
Expression of RNA-binding protein IMP3 (KOC) in benign urothelium and urothelial tumors. Hum Pathol (2008) 1.60
Quantitative imaging of the T cell antitumor response by positron-emission tomography. Proc Natl Acad Sci U S A (2003) 1.60
ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol (2011) 1.59
Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration. Cancer Res (2010) 1.54
Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal. Proc Natl Acad Sci U S A (2011) 1.53
Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. 1993. J Immunol (2012) 1.51
An optimized small molecule inhibitor cocktail supports long-term maintenance of human embryonic stem cells. Nat Commun (2011) 1.45
CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res (2010) 1.42
Differential proton sensitivity of related G protein-coupled receptors T cell death-associated gene 8 and G2A expressed in immune cells. Proc Natl Acad Sci U S A (2005) 1.40
Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci U S A (2002) 1.40
T cell chemotaxis to lysophosphatidylcholine through the G2A receptor. Proc Natl Acad Sci U S A (2003) 1.37
Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells. Proc Natl Acad Sci U S A (2013) 1.37
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A (2010) 1.36
Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc (2009) 1.34
Ionizing radiation induces prostate cancer neuroendocrine differentiation through interplay of CREB and ATF2: implications for disease progression. Cancer Res (2008) 1.33
Neuroendocrine differentiation in prostate cancer. Am J Transl Res (2009) 1.32
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A (2012) 1.32
Gi-independent macrophage chemotaxis to lysophosphatidylcholine via the immunoregulatory GPCR G2A. Blood (2004) 1.31
Purification and direct transformation of epithelial progenitor cells from primary human prostate. Nat Protoc (2011) 1.30
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography. Proc Natl Acad Sci U S A (2009) 1.26
Visualization of a primary anti-tumor immune response by positron emission tomography. Proc Natl Acad Sci U S A (2005) 1.26
Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate (2009) 1.26
Positron emission tomography with computed tomography imaging of neuroinflammation in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2007) 1.25
Vascular abnormalities in mice deficient for the G protein-coupled receptor GPR4 that functions as a pH sensor. Mol Cell Biol (2006) 1.24
Requirement for deoxycytidine kinase in T and B lymphocyte development. Proc Natl Acad Sci U S A (2009) 1.23
Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. Mol Imaging Biol (2004) 1.23
Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells. Blood (2004) 1.22
Hydrophobic surfaces for enhanced differentiation of embryonic stem cell-derived embryoid bodies. Proc Natl Acad Sci U S A (2008) 1.22
An integrated microfluidic culture device for quantitative analysis of human embryonic stem cells. Lab Chip (2008) 1.21
CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol (2008) 1.21
Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen. Int Immunol (2008) 1.19
Androgen receptor splice variant AR3 promotes prostate cancer via modulating expression of autocrine/paracrine factors. J Biol Chem (2013) 1.18
Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via β-catenin signaling. Genes Dev (2012) 1.17
Activation of GPR4 by acidosis increases endothelial cell adhesion through the cAMP/Epac pathway. PLoS One (2011) 1.17
Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress. J Exp Med (2012) 1.16
Stromal epigenetic dysregulation is sufficient to initiate mouse prostate cancer via paracrine Wnt signaling. Proc Natl Acad Sci U S A (2012) 1.16
Photothermal nanoblade for large cargo delivery into mammalian cells. Anal Chem (2011) 1.15
EBV-induced human CD8+ NKT cells suppress tumorigenesis by EBV-associated malignancies. Cancer Res (2009) 1.15
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway. Endocr Relat Cancer (2012) 1.14
Malakoplakia of the prostate on needle core biopsy: a case report and review of the literature. Int J Surg Pathol (2007) 1.13
Cell-autonomous activation of the PI3-kinase pathway initiates endometrial cancer from adult uterine epithelium. Proc Natl Acad Sci U S A (2010) 1.13
Functional domain and motif analyses of androgen receptor coregulator ARA70 and its differential expression in prostate cancer. J Biol Chem (2004) 1.13
Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem (2006) 1.12
Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A (2013) 1.12
Novel PET probes specific for deoxycytidine kinase. J Nucl Med (2010) 1.11
Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol (2010) 1.11
Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol (2010) 1.11
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer (2008) 1.10